Last reviewed · How we verify
NCT05236803: MOTRICITE TSA
Better Understand Motor Deficits Associated With Autism Spectrum Disorders: Development of an Assessment Protocol
NA trial testing Testing of general motor skills, fine motor skills and occulomotricity in Autism Spectrum Disorder in 110 participants. Currently enrolling.
30 October 2026
Quick facts
| Lead sponsor | Centre Hospitalier Charles Perrens, Bordeaux |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 110 |
| Start date | 7 February 2022 |
| Primary completion | 30 October 2026 |
| Estimated completion | 31 March 2027 |
| Sites | 4 locations across France |
Drugs / interventions tested
- Testing of general motor skills, fine motor skills and occulomotricity
- Questionnaires
Conditions studied
- Autism Spectrum Disorder — all drugs for Autism Spectrum Disorder →
Sponsor
Centre Hospitalier Charles Perrens, Bordeaux
Who can join
Adults 6 to 11, any sex, with Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research is a case-control study aiming to characterize motor peculiarities (objective quantitative and qualitative measures) and its psycho-physiological correlates of children with ASD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05236803
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Autism Spectrum Disorder
Currently open trials in the same condition.
- NCT07324057 — The Effects of Preoperative Intranasal Administration of Dexmedetomidine and Esketamine on Negative Postoperative Behavi · NA · recruiting
- NCT07493096 — Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disor · recruiting
- NCT07505290 — Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial f · NA · active not recruiting
- NCT07524192 — A Self-Instructional Online Program for Early Childhood and Elementary Teachers Supporting Autistic Children and Childre · NA · recruiting
- NCT07432776 — Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design · EARLY_PHASE1 · recruiting
Other Centre Hospitalier Charles Perrens, Bordeaux trials
Trials by the same sponsor.
- NCT07309159 — Impact of Cannabis Consumption on Psychotic Symptoms and Reality Monitoring in Patients With Schizophrenia: a Real-life · Phase 1, PHASE2 · not yet recruiting
- NCT07008183 — Perinatal Thymic DYsregulation: Characterization of Perinatal Mood Episodes · NA · recruiting
- NCT06738784 — Evaluation of the Efficiency of the PRPP (Perceive, Recall, Plan and Perform) Task Analysis System on Support and Orient · NA · recruiting
- NCT05381883 — Mental Health of Professionals of the Silver Economy of New Aquitaine : Online Survey of Accommodation Establishments fo · NA · not yet recruiting
- NCT06476873 — Substance Use Disorder in Chemsex Practice · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05236803 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Charles Perrens, Bordeaux
- Last refreshed: 16 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05236803.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing